Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: A meta-analysis

Hypertension Research

Volumn 36, Issue 3, 2013, Pages 252-261

  Chen, Yongfei ^a,b   Meng, Long ^a   Shao, Hua ^b   Yu, Feng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

aliskiren; efficacy; hypertension; meta analysis; safety

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FUMARATES; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84874593262     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.185     Document Type: Article

References (45)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
2. Poulter N. Global risk of cardiovascular disease. Heart 2003; 89(Suppl 2): ii2-ii5; discussion ii35-37.
3. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc 2002; 94: 7S-15S.
4. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. The Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360.
5. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005; 45: 163-169.
6. Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy Rev Cardiovasc Med 2006; 7: 45-54.
7. Skeggs Jr LT, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439-453.
8. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983-991.
9. Wood JM, Maibaum J, Rahuel J, Grü tter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
10. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
11. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
13. Hopewell S, McDonald S, Clarke M, Egger M. Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev 2007; 2: MR000010.
14. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses Lancet 2000; 356: 1228-1231.
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. Management of arterial hypertension of the European Society of Hypertension, European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
16. World Health Organization. International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials 1996; 17: 1-12.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-560.
19. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-320.
20. Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 163-175.
21. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
22. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
23. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-229.
24. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
25. Puig JG, Schunkert H, Taylor AA, Boye S, Jin J, Keefe DL. Evaluation of the dose-response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin Ther 2009; 31: 2839-2850.
26. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
27. Verdecchia P, Calvo C, Möckel V, Keeling L, Satlin A. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007; 16: 381-391.
28. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217.
29. An eight-week double-blind, multi-center, randomized, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ displayFile.dotrialResult=2933.
30. An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. http://www.novctrd.com/ctrdWebApp/ clinicaltrialrepository/displayFile.dotrialResult=3000.
31. Zheng Z, Shi H, Jia J, Li D, Lin S. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12: 102-112.
32. Gao D, Ning N, Niu X, Wei J, Sun P, Hao G. Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am J Hypertens 2011; 24: 613-621.
33. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1: 264-277.
34. Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. J Hum Hypertens 2010; 24: 721-729.
35. Dahlö f B, Anderson D, Arora V, Bush C, Keefe D. Aliskiren a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J Clin Hypertens 2007; 9: A157.
36. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
37. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Papst CC, Smith BA, Dahlö f B. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
38. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
39. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens 2010; 12: 765-775.
40. Dü sing R, Weisser B, Mengden T, Vetter H. Changes in antihypertensive therapy-the role of adverse effects and compliance. Blood Press 1998; 7: 313-315.
41. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
42. Dickerson LM, Gibson MV. Management of hypertension in older persons. Am Fam Physician 2005; 71: 469-476.
43. Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Böhm M, Gimpelewicz C, Botha J, Moores S, Lewis EF, Rattunde H, Maggioni A; on behalf of the ASTRONAUT investigators and study coordinators. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011; 13: 100-106.
44. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
45. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011; 13: 107-114.